A detailed history of Sumitomo Mitsui Trust Holdings, Inc. transactions in Argenx Se stock. As of the latest transaction made, Sumitomo Mitsui Trust Holdings, Inc. holds 1,633 shares of ARGX stock, worth $1.03 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,633
Previous 1,630 0.18%
Holding current value
$1.03 Million
Previous $700,000 26.43%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$434.22 - $551.9 $1,302 - $1,655
3 Added 0.18%
1,633 $885,000
Q2 2024

Jul 19, 2024

SELL
$356.01 - $451.55 $1,780 - $2,257
-5 Reduced 0.31%
1,630 $700,000
Q1 2024

Apr 19, 2024

SELL
$356.95 - $413.29 $41,049 - $47,528
-115 Reduced 6.57%
1,635 $643,000
Q4 2023

Jan 30, 2024

BUY
$338.91 - $506.01 $241,642 - $360,785
713 Added 68.76%
1,750 $665,000
Q3 2023

Oct 30, 2023

SELL
$369.35 - $548.43 $207,944 - $308,766
-563 Reduced 35.19%
1,037 $509,000
Q2 2023

Jul 31, 2023

SELL
$360.14 - $422.58 $38,174 - $44,793
-106 Reduced 6.21%
1,600 $623,000
Q1 2023

Apr 27, 2023

BUY
$334.23 - $403.65 $570,196 - $688,626
1,706 New
1,706 $635,000
Q4 2021

Feb 02, 2022

SELL
$272.01 - $353.03 $282,346 - $366,445
-1,038 Closed
0 $0
Q3 2021

Oct 25, 2021

SELL
$295.0 - $350.58 $2,950 - $3,505
-10 Reduced 0.95%
1,038 $313,000
Q2 2021

Aug 02, 2021

SELL
$257.11 - $319.92 $25,196 - $31,352
-98 Reduced 8.55%
1,048 $316,000
Q1 2021

Apr 30, 2021

BUY
$268.3 - $380.31 $11,805 - $16,733
44 Added 3.99%
1,146 $316,000
Q4 2020

Feb 05, 2021

SELL
$248.13 - $308.36 $30,519 - $37,928
-123 Reduced 10.04%
1,102 $324,000
Q3 2020

Oct 30, 2020

BUY
$215.51 - $272.51 $263,999 - $333,824
1,225 New
1,225 $322,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $34.8B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Sumitomo Mitsui Trust Holdings, Inc. Portfolio

Follow Sumitomo Mitsui Trust Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sumitomo Mitsui Trust Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Sumitomo Mitsui Trust Holdings, Inc. with notifications on news.